Recent Updates
Recently added Catalysts

Barinthus Biotherapeutics plc

BRNS
OvervaluedPharma · Clinical
FDA catalysts, PDUFA dates & pipeline intelligence
$0.74
▲ 0 · 0%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full BRNS financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $0.5152W HIGH $1.83
Volume
378.15 K
Value Traded
12.67 K
Short % Float
0.03%
-2.49%Week
+27.06%1 Month
+10.3%3 Month
+17.66%6 Month
-95.57%5 Year
-94.96%All Time

Cash Data

Unlock BRNS cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
30.23 M
EPS (TTM)
-1.02
P/E Ratio
-
Ent. Value
-29.06 M
Total Shares
40.85 M
Float Shares
39.43 M
Insiders
3.48%
Institutions
19.05%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 2a data readout
CLY-101 (Balomenib)
Type 1 diabetes, Type 2 diabetes
Phase 2aSmall MoleculesEndocrine System
Unlock every BRNS catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

BRNS Catalyst Timeline

Dated clinical, regulatory and corporate events for Barinthus Biotherapeutics plc

Catalyst Timeline

Dated clinical, regulatory & corporate events for Barinthus Biotherapeutics plc

215Total events
3Upcoming
67Tier-1 (high impact)
2021 to 2027Coverage

Upcoming catalysts 2

T1Topline Readout
Subscribe to view catalyst details
VTP-1000
T2Runway Guidance Update
Subscribe to view catalyst details

Event history 50

●AcquisitionCorporate
Scheme Exchange Ratio determined at 0.111
source ↗
▲Enrollment CompleteVTP-1000Trial
Completed enrollment of 42 planned subjects in Phase 1 AVALON trial
celiac diseasesource ↗
◆AcquisitionCorporate
Proposed combination with Clywedog progressing towards closing
source ↗
●Quarterly UpdateCorporate
Q2 2026 financial results reported
source ↗
●Runway Guidance UpdateCorporate
Cash runway guidance: at least 12 months from issuance
source ↗
●Other Regulator MilestoneEx-US Regulatory
Nasdaq granted extension to regain bid price compliance until Dec 28, 2026
source ↗
◆AcquisitionCorporate
Proposed combination with Clywedog Therapeutics progressing towards closing
source ↗
◆Management ChangeCorporate
Doug Swirsky appointed CFO effective May 1, 2026
source ↗
●Quarterly UpdateCorporate
First quarter 2026 financial results reported
source ↗
◆Topline ReadoutVTP-1000Clinical Data
MAD portion data expected
celiac diseasesource ↗
Unlock the full BRNS catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How BRNS actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-10-09VTP-1000 (Single Ascending Dose) Phase 1 Single Ascending Dose data readout Phase 1
Unlock 3 more BRNS historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

D37 / 100
Pipeline Score
$7M
Pipeline Value
Overvalued
Valuation Signal
3
Drugs Scored
0.2x
rNPV / MCap
Barinthus Biotherapeutics plc faces pipeline headwinds (37/100), with $326M risk-adjusted pipeline value, led by ChAdOx1-HPV in HPV Infection (Phase 1).
Showing 1 of 3 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
ChAdOx1-HPV Monoclonal antibodyCompletedNCT04607850HPV InfectionPhase 1 COMPLETED 108Jan 16, 2024
Unlock the BRNS pipeline intelligence model
Every scored asset with PTRS, rNPV, enrollment velocity and trial design quality.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every BRNS program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
VTP-1000 Celiac DiseasePhase 12025-12-10well tolerated with no treatment-related SAEs; dose-dependent pharmacological effect observed; enrolled 18 patients in three placebo-controlled cohorts of ascending dosesRead MoreBarinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac DiseaseRead More
Scroll for more · summaries link to the source press release
Unlock every BRNS trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock BRNS insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
John SmithCEOBuy 50,000 150,000 held$45.50 01/10/2026
Unlock the full BRNS insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in BRNS

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in BRNS for Q2 2026.
Unlock every fund holding BRNS
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in BRNS
Shares held by hedge funds each quarter, and who bought or sold.

BRNS Institutional Ownership Trends

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock BRNS option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live BRNS option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock BRNS options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How BRNS ranks across every disease it competes in

Competitive Position is a premium feature
See how BRNS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

BRNS News

About Barinthus Biotherapeutics plc

Germantown, MD 14 employees barinthusbio.com
Headquarters20400 CENTURY BLVD, GERMANTOWN, MD, 20874
BIOPHARMAWATCH ELITE PLUS
Trade the next BRNS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime